Managing hematologic toxicities in the oncology patient

Area of Science:

• Oncology
• Hematology

Background:

• Antineoplastic therapy frequently causes myelosuppression, leading to neutropenia and anemia.
• These conditions increase infection risk, fatigue, and can necessitate treatment delays or dose reductions.

Purpose of the Study:

• To discuss the management of neutropenia and anemia secondary to antineoplastic therapy.
• To review new medications and nursing considerations for supportive care.

Main Methods:

• Literature review on myelosuppression management.
• Discussion of hematopoietic growth factors and novel therapeutic agents.
• Exploration of nursing interventions.

Main Results:

• Hematopoietic growth factors are effective in mitigating neutropenia and anemia.
• Early intervention and appropriate management can reduce complications.
• New medications offer improved efficacy and safety profiles.

Conclusions:

• Effective management of myelosuppression is crucial for maintaining treatment continuity and improving patient quality of life.
• Hematopoietic growth factors and emerging therapies play a vital role in supportive care.
• Nursing plays a key role in patient monitoring and management of side effects.